Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

United Therapeutics (UTHR) Debt to Equity (2017 - 2025)

United Therapeutics' Debt to Equity history spans 14 years, with the latest figure at $0.03 for Q1 2025.

  • For Q1 2025, Debt to Equity fell 73.86% year-over-year to $0.03; the TTM value through Mar 2025 reached $0.03, down 73.86%, while the annual FY2024 figure was $0.05, 60.2% down from the prior year.
  • Debt to Equity for Q1 2025 was $0.03 at United Therapeutics, down from $0.05 in the prior quarter.
  • Across five years, Debt to Equity topped out at $0.23 in Q1 2021 and bottomed at $0.03 in Q1 2025.
  • The 5-year median for Debt to Equity is $0.16 (2023), against an average of $0.15.
  • The largest annual shift saw Debt to Equity fell 14.24% in 2021 before it crashed 73.86% in 2025.
  • A 5-year view of Debt to Equity shows it stood at $0.2 in 2021, then dropped by 17.47% to $0.17 in 2022, then decreased by 29.87% to $0.12 in 2023, then crashed by 60.2% to $0.05 in 2024, then plummeted by 36.89% to $0.03 in 2025.
  • Per Business Quant, the three most recent readings for UTHR's Debt to Equity are $0.03 (Q1 2025), $0.05 (Q4 2024), and $0.07 (Q3 2024).